# Biogen

Type: Company (BIIB)

Source: GetYourBrief — https://getyourbrief.com/entity/biogen
Canonical HTML page: https://getyourbrief.com/entity/biogen

## Timeline

- **2026-10**: Expected Deal Close — The all-stock merger is anticipated to close, pending shareholder and regulatory approvals.
- **2026-08-03**: Merger and Earnings Announcement — Supernus unveils definitive agreement to merge with Indivior and releases Q2 2026 financial results.
- **2026-07-28**: High Court grants permission for judicial review — Judge Cian Ferriter allows Emily Felix's challenge against the HSE and Minister for Health to proceed, citing arguable grounds regarding the delay.
- **2026-07-28**: High Court grants permission for judicial review — Judge Cian Ferriter allows Emily Felix's challenge against the HSE and Minister for Health to proceed, citing arguable grounds regarding the delay.
- **2026-03-23**: Official Rollout — Scotland officially begins screening all newborns for the rare muscle disease.
- **2026**: Data Evaluation — Expected first review of screening efficacy and treatment referral rates in Scotland.
- **2025-12**: NCPE pharmacoeconomic evaluation completed — The National Centre for Pharmacoeconomics delivers its assessment of Skyclarys' cost-effectiveness to the HSE.
- **2025-12**: NCPE pharmacoeconomic evaluation completed — The National Centre for Pharmacoeconomics delivers its assessment of Skyclarys' cost-effectiveness to the HSE.
- **2025-Q4**: Scottish Policy Review — Scottish health officials evaluate the feasibility of independent implementation.
- **2024-08**: HSE reimbursement application filed — Biogen submits a formal pricing and reimbursement application to the HSE to add Skyclarys to the public drug list.
- **2024-08**: HSE reimbursement application filed — Biogen submits a formal pricing and reimbursement application to the HSE to add Skyclarys to the public drug list.
- **2024-02**: European market authorisation — The European Commission grants centralised marketing authorisation for Biogen's Skyclarys (omaveloxolone) for patients over 16.
- **2024-02**: European market authorisation — The European Commission grants centralised marketing authorisation for Biogen's Skyclarys (omaveloxolone) for patients over 16.
- **2024**: Clinical Advocacy — Intense campaigning by rare disease groups for the inclusion of SMA in UK-wide screening.
- **2010**: Diagnosis with Friedreich's ataxia — Emily Felix, then 12 years old, is diagnosed with the rare, progressive neuromuscular disease.

## Recent coverage (5 stories, network-wide)

### Supernus–Indivior Merger Creates 11-Drug CNS Giant, $125M Synergy Target
2026-08-04 00:21:58 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 4

Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.
Full story: https://gethealthbrief.com/story/supernus-indivior-cns-merger-125m-synergy

### Biogen’s Skyclarys Faces Irish Access Battle as 12 EU Nations Already Fund It
2026-08-03 15:05:46 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biogen’s orphan drug for Friedreich’s ataxia, approved by the EMA since February 2024, remains mired in Irish reimbursement ambiguity, prompting a patient’s judicial review and highlighting the EU’s fragmented market access for novel therapies.
Full story: https://getbiobrief.com/story/biogen-skyclarys-irish-access-battle-12-eu

### Patient Sues HSE After 23-Month Delay on Drug Available in 12 EU States
2026-08-03 15:05:07 · Sector: legal · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Emily Felix, 28, launches judicial review against the HSE for failing to decide on funding for Biogen's Friedreich's ataxia drug for nearly two years, despite EMA approval and availability across a dozen EU nations.
Full story: https://getlegalbrief.com/story/patient-sues-hse-23-month-delay-drug-12-eu

### Rare Disease Patient ‘Fighting for Survival’ as HSE Stalls Drug Access 23 Months
2026-08-03 15:04:56 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A woman with Friedreich’s ataxia sues the HSE over an unacceptably prolonged reimbursement decision for omaveloxolone, a treatment that could slow her decline and that is already standard care in 12 other European countries.
Full story: https://gethealthbrief.com/story/rare-disease-patient-fighting-survival-hse-delay

### Scotland Breaks Ranks to Launch UK's First Newborn Screening for Muscle Disease
2026-03-23 02:10:57 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for a rare genetic muscle disease. This landmark policy shift aims to identify affected infants at birth, allowing for immediate intervention and treatment before the onset of irreversible physical symptoms.
Full story: https://gethealthbrief.com/story/scotland-first-uk-newborn-screening-rare-muscle-disease

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.